These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23298374)

  • 1. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report.
    Noda Y; Miyoshi T; Oe H; Ohno Y; Nakamura K; Toh N; Kohno K; Morita H; Kusano K; Ito H
    Cardiovasc Diabetol; 2013 Jan; 12():8. PubMed ID: 23298374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals - a randomized cross-over trial.
    Miyoshi T; Noda Y; Ohno Y; Sugiyama H; Oe H; Nakamura K; Kohno K; Ito H
    Biomed Pharmacother; 2014 Oct; 68(8):1071-7. PubMed ID: 25458786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
    Eliasson B; Möller-Goede D; Eeg-Olofsson K; Wilson C; Cederholm J; Fleck P; Diamant M; Taskinen MR; Smith U
    Diabetologia; 2012 Apr; 55(4):915-25. PubMed ID: 22237690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction.
    Yunoki K; Nakamura K; Miyoshi T; Enko K; Kohno K; Morita H; Kusano KF; Ito H
    Atherosclerosis; 2011 Aug; 217(2):486-91. PubMed ID: 21592480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.
    Torimoto K; Okada Y; Mori H; Otsuka T; Kawaguchi M; Matsuda M; Kuno F; Sugai K; Sonoda S; Hajime M; Tanaka K; Arao T; Tanaka Y
    Cardiovasc Diabetol; 2015 Feb; 14():25. PubMed ID: 25849903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study.
    Ohno Y; Miyoshi T; Noda Y; Oe H; Toh N; Nakamura K; Kohno K; Morita H; Ito H
    Cardiovasc Diabetol; 2014 Apr; 13():71. PubMed ID: 24708775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
    Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
    Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.
    Eleftheriadou I; Grigoropoulou P; Katsilambros N; Tentolouris N
    Curr Diabetes Rev; 2008 Nov; 4(4):340-56. PubMed ID: 18991602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
    Mita T; Katakami N; Yoshii H; Onuma T; Kaneto H; Osonoi T; Shiraiwa T; Kosugi K; Umayahara Y; Yamamoto T; Yokoyama H; Kuribayashi N; Jinnouchi H; Gosho M; Shimomura I; Watada H;
    Diabetes Care; 2016 Jan; 39(1):139-48. PubMed ID: 26628419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone (GH) treatment decreases postprandial remnant-like particle cholesterol concentration and improves endothelial function in adult-onset GH deficiency.
    Twickler TB; Wilmink HW; Schreuder PC; Cabezas MC; van Dam PS; Koppeschaar HP; Erkelens DW; Dallinga-Thie GM
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4683-9. PubMed ID: 11134128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.
    Liu X; Liu Y; Liu H; Li H; Yang J; Hu P; Xiao X; Liu D
    Front Endocrinol (Lausanne); 2021; 12():694390. PubMed ID: 34616361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alogliptin: a review of its use in patients with type 2 diabetes mellitus.
    Keating GM
    Drugs; 2015 May; 75(7):777-96. PubMed ID: 25855222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
    Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasting remnant lipoproteins can predict postprandial hyperlipidemia.
    Nagata T; Sugiyama D; Kise T; Tsuji S; Ohira H; Sato I; Yamamoto M; Kohsaka H; Kawano S; Yamashita S; Ishikawa Y; Fujioka Y
    Lipids Health Dis; 2012 Oct; 11():146. PubMed ID: 23110373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
    Kurozumi A; Okada Y; Satoh H; Inoue I; Chimori H; Akita E; Shiraiwa T; Fujitani Y; Mita T; Gosho M; Watada H
    Endocr J; 2018 Apr; 65(4):415-425. PubMed ID: 29367471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunction.
    Westphal S; Abletshauser C; Luley C
    Coron Artery Dis; 2009 Jan; 20(1):81-5. PubMed ID: 19060628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2010 Oct; 70(15):2051-72. PubMed ID: 20883057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles.
    Wilmink HW; Twickler MB; Banga JD; Dallinga-Thie GM; Eeltink H; Erkelens DW; Rabelink TJ; Stroes ES
    Cardiovasc Res; 2001 Jun; 50(3):577-82. PubMed ID: 11376633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.